Pr Gallien
Créteil, 94000, France
Location status: Recruiting
Location contact
Sebastien Gallien, PhD
CONTACT
NCT Number: NCT03875703
Introduction: Vaccination is a powerful weapon in the fight against infectious diseases, which has led to dramatic reduction in mortality and complications from some diseases. In this respect, vaccination is a real worldwide public health challenge (WHO). Thus, vaccine research benefits from an exponential development of knowledge in immunology and biotechnology. In particular, the advent of recent tools ("omics", new cytometric assays) and the description of new categories of immune cells (Tfh, BReg...) have revolutionized the characterization of immune responses, particularly post-vaccination. To study of the immune response following vaccination remains essential in order to define the immunological correlates to vaccine protection. This response also varies according to parameters related to the vaccine (type, adjuvant, dose, regimen…) and to the vaccinated host (genetics, age, morbidity, treatment …). Analyzing with new generation immune assays, new data on immunological responses post-vaccination from a clinical cohort is therefore essential to better define these correlates.
Objective: To develop new vaccines (HIV, emerging infectious diseases) the investigators use a "System vaccinology" method to decipher the mechanisms of immune responses set up against vaccines currently being developed or marketed, specifically in specific populations (patients with primary immune deficiency, sickle cell patients, solid organ transplanted patients, COPD).
Method: Description of the genetic, molecular and cellular mechanisms of the immune response to vaccines recommended for adults, in particular influenza and pneumococcal vaccines, but also other mandatory vaccines (MMR,...) or vaccine for travelers (yellow fever, ...) as part of routine care in different population categories (healthy subjects, HIV+ subjects, COPD patients, …), using qualitative and quantitative immunological assays: transcriptional analysis of the dynamic innate immune response, analysis of the lymphocytes B & T responses (phenotype, repertoire analysis, functional analysis including T reg and TFH populations, antibody response), genetic analysis in the context of primary immune deficiencies) Conclusion: The data generated will allow the best possible analysis of vaccine responses according to vaccines and vaccinated populations, providing important information for the research developed within the department.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Créteil, 94000, France
Location status: Recruiting
Sebastien Gallien, PhD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Hour 24 after vaccination
Transcriptomic analysis performed from whole blood samples
Time frame: at Day 0, Day 7, Day 14 and Month 1 after vaccination
(phenotype, analysis of the repertoire B, functional analysis, antibody response, plasmablastic response)
Time frame: at Day 0, Day 7, Day 14 and Month 1 after vaccination
(phenotype, T repertoire analysis, functional analysis, especially of the Treg and TFH populations)
Time frame: at Month 1
Contact information is provided by the study sponsor or research team.
Assistance Publique - Hôpitaux de Paris
Other
Biological Collection for Studying Vaccine-induced Immune Responses
Acronym: BioCol-VIR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05102669
COVID-19, Coronaviridae Infections
Roma, Italy
View Trial DetailsNCT02933931
Durability, Immune Response
View Trial DetailsNCT07236034
Vaccination, Vaccination Promotion
Worcester, Massachusetts, United States
View Trial DetailsNCT07636525
Vaccination
Cincinnati, Ohio, United States
View Trial Details